Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of CYP3A4 Induction on ALKS 5461 PK
NCT02545439Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine and samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Primary endpoints: Area Under the Curve to Infinity up to 72 hours, Area Under the Curve to Last Measurable Concentration up to 72 hours and 1 more. Started Jul 2015; status: completed.
02
Drugs
buprenorphinesamidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02545439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545439.